The Beauty Health pany(SKIN) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - For Q4 2025, total revenue was $82.4 million, a decrease of 1.3% year-over-year, but an improvement from the double-digit decline in Q3 [10] - Consumables revenue increased to $57.7 million from $56.7 million, representing a growth of 1.7% year-over-year [10] - Device revenue was $24.7 million, down 7.9% year-over-year, but showed improvement compared to Q3 [10] - Adjusted gross margin expanded to 67.4%, while GAAP gross margin increased to 64.4% [11] - Adjusted EBITDA for Q4 was $15 million, up from $9 million in the prior year, indicating a margin expansion of approximately 700 basis points [11] - For the full year, net sales were $300.8 million, down from $334.3 million in 2024, with consumables revenue totaling $212.7 million and device revenue at $88.1 million [21] Business Line Data and Key Metrics Changes - The installed base of systems reached over 36,000 globally, with more than 1,000 devices placed in Q4 [12] - The capital equipment segment continues to face pressure, consistent with broader macroeconomic conditions [10] Market Data and Key Metrics Changes - The U.S. med spa market has grown from approximately 1,600 locations in 2010 to over 13,000 today, indicating significant market expansion [7] - Consumer demographics are evolving, with increased engagement from men, Gen Z, and younger consumers [7] Company Strategy and Development Direction - The company aims to shift from a device placement model to a device utilization model to drive long-term growth [9] - Key strategic priorities include salesforce excellence, marketing discipline, and focused innovation [14] - The company plans to enhance its commercial model by improving provider education and marketing strategies [16][17] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about the aesthetic category, noting that demand for non-invasive treatments continues to grow globally [12] - The first half of 2026 is expected to be modestly below the prior year, with a stronger trajectory anticipated in the second half [19][25] - The company expects to return to growth in 2027 as operational changes take effect [28] Other Important Information - The company has strengthened its balance sheet and improved its cost structure, exiting 2025 as a stronger entity [20] - Adjusted EBITDA for the full year increased significantly to $45.1 million from $12.3 million in the prior year [21] Q&A Session Summary Question: Guidance for 2026 and sales organization overhaul - Management expects revenue to be flat year-on-year, with adjusted EBITDA slightly below 2025 due to reinvestment in R&D [32][33] Question: Underlying market environment assumptions - Consumer spending remains selective, with a focus on clinically proven results at accessible price points [37] - The medical segment continues to grow, driven by med spas using HydraFacial to attract patients [39] Question: Churn trends and marketing to new demographics - Churn improved in Q4 to about 1.1%, with expectations to hold flat year-over-year [44] - The company is addressing the needs of new demographics entering the category, focusing on outcome-driven protocols [47] Question: New system launch timeline and features - The next-generation HydraFacial is planned for launch in 2028, aimed at providing compelling reasons for upgrades [53] Question: Pricing strategy and consumable utilization - A 5% price increase on consumables was well-received, with no significant complaints [73] - Providers who understand how to prescribe boosters use them three times more than those who do not [74]